Neurovascular Hypertension & Kidney Disease Laboratory, Baker IDI Heart & Diabetes Institute and Heart Centre, Alfred Hospital, Melbourne, Australia.
Am J Hypertens. 2011 Jun;24(6):635-42. doi: 10.1038/ajh.2011.35. Epub 2011 Mar 10.
Essential hypertension remains one of the biggest challenges in medicine with an enormous impact on both individual and society levels. With the exception of relatively rare monogenetic forms of hypertension, there is now general agreement that the condition is multifactorial in nature and hence requires therapeutic approaches targeting several aspects of the underlying pathophysiology. Accordingly, all major guidelines promote a combination of lifestyle interventions and combination pharmacotherapy to reach target blood pressure (BP) levels in order to reduce overall cardiovascular risk in affected patients. Although this approach works for many, it fails in a considerable number of patients for various reasons including drug-intolerance, noncompliance, physician inertia, and others, leaving them at unacceptably high cardiovascular risk. The quest for additional therapeutic approaches to safely and effectively manage hypertension continues and expands to the reappraisal of older concepts such as renal denervation. Based on the robust preclinical and clinical data surrounding the role of renal sympathetic nerves in various aspects of BP control very recent efforts have led to the development of a novel catheter-based approach using radiofrequency (RF) energy to selectively target and disrupt the renal nerves. The available evidence from the limited number of uncontrolled hypertensive patients in whom renal denervation has been performed are auspicious and indicate that the procedure has a favorable safety profile and is associated with a substantial and presumably sustained BP reduction. Although promising, a myriad of questions are far from being conclusively answered and require our concerted research efforts to explore the full potential and possible risks of this approach. Here we briefly review the science surrounding renal denervation, summarize the current data on safety and efficacy of renal nerve ablation, and discuss some of the open questions that need to be addressed in the near future.
原发性高血压仍然是医学领域面临的最大挑战之一,对个人和社会层面都有重大影响。除了相对罕见的遗传性高血压形式,目前普遍认为高血压是多因素的,因此需要针对潜在病理生理学的多个方面进行治疗。因此,所有主要指南都提倡将生活方式干预和联合药物治疗相结合,以达到目标血压水平,从而降低受影响患者的整体心血管风险。尽管这种方法对许多人有效,但由于药物不耐受、不遵医嘱、医生惯性等各种原因,相当数量的患者无法达到目标,使他们面临不可接受的高心血管风险。因此,人们一直在寻求额外的治疗方法,以安全有效地治疗高血压,并重新评估旧的概念,如肾去神经术。基于强有力的临床前和临床数据,围绕肾交感神经在血压控制的各个方面的作用,最近的研究进展导致了一种新的基于射频(RF)能量的导管介入方法的发展,该方法可以选择性地靶向和破坏肾神经。在已经接受肾去神经术的少数不受控制的高血压患者中,现有的证据是有希望的,表明该手术具有良好的安全性,与显著且可能持续的血压降低相关。尽管前景广阔,但仍有许多问题尚未得到明确回答,需要我们共同努力,探索这种方法的全部潜力和可能存在的风险。在这里,我们简要回顾了肾去神经术的相关科学,总结了肾神经消融的安全性和有效性的现有数据,并讨论了一些需要在不久的将来解决的开放性问题。